Cancer Research

International researchers have identified a five-week chemoradiotherapy protocol that allows four out of five patients to avoid major surgery while maintaining their quality of life. This paradigm shift in oncology marks a departure from the traditional approach, where radical excision was

The persistent failure of conventional neuro-oncology treatments to extend median survival beyond eighteen months has catalyzed a profound transition from targeting individual malignant cells to orchestrating the total disruption of the glioma microenvironment. This shift represents more than just

The scalability of NGSE-Corr suggests that the method becomes increasingly powerful and reliable when applied to large-scale clinical datasets and patient populations. This innovative approach addresses a fundamental limitation in modern medical diagnostics where the push for quantitative data

The historical classification of the PVT1 locus as a non-coding region has been overturned by evidence showing it produces functional proteins that dictate the survival of malignant cells. For decades, the oncology community has viewed the MYC gene as the most frustrating obstacle in cancer

A major challenge in pharmaceutical development is the high failure rate of programs that stall because a target protein’s structure cannot be mapped. For many years, the pharmaceutical industry relied heavily on physical laboratory experiments that were both time-consuming and prone to human

A record 383 vials of LYMPHIR were ordered in July, establishing a new performance benchmark for the company’s expanded 29-member nationwide sales infrastructure. This milestone represents a significant pivot for Citius Pharmaceuticals as it transitions from a clinical-stage entity into a